Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Soliris (eculizumab)
pCPA File Number:
21270
Negotiation Status:
Concluded without agreement
Indication(s):
Neuromyelitis optica spectrum disorder (NMOSD)
Sponsor/Manufacturer:
Alexion Pharma GMBH
CADTH Project Number:
SR0640
pCPA Engagement Letter Issued:
2021-03-02
Negotiation Process Concluded:
2022-12-12